Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 3

LA JOLLA PHARMACEUTICAL CO

Form 3 July 08, 2015

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005

Estimated average burden hours per

response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement LA JOLLA PHARMACEUTICAL CO [LJPC] Chawla Lakhmir S (Month/Day/Year) 07/01/2015 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O LA JOLLA (Check all applicable) **PHARMACEUTICAL** COMPANY,, 10182 TELESIS 10% Owner Director COURT, 6TH FLOOR _X__ Officer Other (give title below) (specify below) (Street) 6. Individual or Joint/Group Chief Medical Officer Filing(Check Applicable Line)

SAN DIEGO, CAÂ 92121

(State)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)

(City)

2. Amount of Securities Beneficially Owned (Instr. 4)

Ownership C Form: (

4. Nature of Indirect Beneficial Ownership

Reporting Person

Person

X Form filed by One Reporting

Form filed by More than One

Form: (Instr. 5)
Direct (D)
or Indirect

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Zip)

SEC 1473 (7-02)

(I) (Instr. 5)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

3. Title and Amount of 1. Title of Derivative Security 2. Date Exercisable and 4. 6. Nature of Indirect 5. **Expiration Date** Securities Underlying Ownership Beneficial Ownership (Instr. 4) Conversion (Month/Day/Year) or Exercise Form of (Instr. 5) Derivative Security (Instr. 4) Price of Derivative Derivative Security:

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	(1)	02/06/2025	Common Stock	60,000	\$ 17.34	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Chawla Lakhmir S C/O LA JOLLA PHARMACEUTICAL COMPANY, 10182 TELESIS COURT, 6TH FLOOR SAN DIEGO, Â CA Â 92121	Â	Â	Chief Medical Officer	Â	

Signatures

/s/ Chester S. Zygmont, III as attorney-in-fact for Lakhmir S. Chawla 07/08/2015

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents an option to purchase a total of 60,000 shares of the Issuer's Common Stock previously issued pursuant to a consultancy

Date

(1) arrangement. The option was fully vested with respect to one quarter of the underlying shares on the date of grant, with the remaining shares vesting quarterly thereafter over the next three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2